Shares of Hims & Hers Health experienced a decline in Tuesday afternoon trading, closing 1.6% lower at $30.52. The downturn followed an announcement from e-commerce giant Amazon regarding its entry into the competitive GLP-1 weight-management market through its One Medical service. The stock opened the session at $28.31 and reached an intraday low of $28.01, reflecting investor concerns over increased competitive pressure on the telehealth firm's weight-loss segment.
Strategic Pivot Amid Regulatory Scrutiny
Hims & Hers is executing a significant strategic shift, moving away from its previous model of offering compounded GLP-1 medications. In this model, pharmacies would create tailored drug formulations for individual patients. The company is now transitioning toward providing branded, FDA-approved pharmaceutical options. This pivot was signaled in March when Hims & Hers announced it would cease marketing compounded GLP-1s and struck a partnership with Novo Nordisk to add the drugs Ozempic and Wegovy to its digital health platform.
Amazon's Integrated Care Model
Amazon's newly launched program integrates primary care, pharmacy services, and virtual obesity treatment. Amazon Pharmacy plans to offer same-day prescription delivery across nearly 3,000 cities, with an ambitious target of expanding to 4,500 locations by the end of the year. The service provides 24/7 prescription renewals, starting at a cost of $29 for patients who already have an existing GLP-1 prescription. Tanvi Patel, Vice President and General Manager of Amazon Pharmacy, emphasized that "fast, convenient medication access and clear, transparent pricing" are central to the initiative.
While Amazon's stock edged approximately 1.2% higher, other major players in the weight-loss drug space faced downward pressure. Shares of Eli Lilly, maker of Mounjaro and Zepbound, slipped 1.3%. U.S.-listed shares of Novo Nordisk, the company behind Ozempic and Wegovy, declined 2.3%. Both pharmaceutical giants are leaders in the GLP-1 drug market, which is widely prescribed for managing type 2 diabetes and obesity.
Mounting Challenges and Legal Scrutiny
Hims & Hers faces this new competitive threat from Amazon amid existing turbulence. Earlier this year, the company had shifted its focus toward lower-cost GLP-1 alternatives. However, this strategy encountered significant legal and regulatory headwinds. A Reuters report in February indicated that Hims & Hers had introduced a compounded $49 version of Novo Nordisk's Wegovy pill, a move that prompted immediate backlash from the Danish pharmaceutical company.
Andrew Dudum, CEO of Hims & Hers, framed the company's strategic shift in March differently, pointing to "tremendous growth opportunities" within the expanding market for branded GLP-1 medications. The company's current position involves a bet that it can retain customers through its integrated care model, personalized coaching, and digital convenience, even as Amazon, Novo Nordisk, and Eli Lilly enhance their own direct-to-consumer offerings.
Analyst Perspectives and Market Differentiation
Financial analysts did not universally view Amazon's new service as a direct substitute for Hims & Hers. Citigroup noted that Amazon's $29 on-demand offering is targeted solely at prescription renewals, not new patient prescriptions. The bank characterized the service as "not a replacement" for comprehensive platforms like Hims & Hers and maintained a Neutral rating with a $24 price target on the company's stock.
Investor attention is also turning toward peptide-based therapies. The U.S. Food and Drug Administration has scheduled a meeting of its Pharmacy Compounding Advisory Committee for July 23-24. The committee will evaluate whether several peptide substances—including BPC-157, KPV, TB-500, and MOTs-C—should be added to the 503A Bulks List. This list defines which substances compounding pharmacies are permitted to use.
Michael Cherny, an analyst at Leerink Partners, suggested to Reuters last week that a potential FDA decision could be "a clear positive for Hims," though he cautioned that it would "not immediately translate into revenue." Pat Carroll, Chief Medical Officer at Hims & Hers, stated the company is exploring access to peptide therapies with a commitment to operating within FDA guidelines and prioritizing consumer safety.
Regulatory Uncertainty and Financial Outlook
The path forward for Hims & Hers is complex. Regulatory timelines remain uncertain, Amazon's expanding footprint in healthcare delivery presents a formidable challenge, and the company must demonstrate that its international expansion and shift to branded drugs can offset declining sales from its compounded GLP-1 business. A Reuters report in March highlighted analyst skepticism over whether this strategic expansion would materialize quickly enough to counter margin pressures.
Hims & Hers is scheduled to report its first-quarter financial results after the market closes on May 11. Investors will closely scrutinize key metrics, including revenue from the weight-loss segment, subscriber retention rates, and any indications of the strength of its GLP-1 strategy as Amazon continues to advance into similar territory.
